AuntMinnie

NOVEMBER 20, 2024

Telix Pharmaceuticals is expanding its theranostic pipeline with newly acquired assets targeting fibroblast activation protein (FAP) in nuclear medicine. FAP is a pan-cancer marker expressed in the tumor microenvironment of epithelial cancers and on the surface of some specific cancer types, including sarcomas and mesotheliomas.

Nuclear Medicine 130

Nuclear Medicine Pharmaceutical Radiopharmaceuticals Clinic 130

Radiology Business

SEPTEMBER 20, 2023

Backers include societies representing radiologists and nuclear medicine professionals, device manufacturers, patient advocacy groups, and pharmaceutical companies.

Nuclear Medicine 264

Nuclear Medicine Pharmaceutical Diagnostic Imaging Diagnostic 264

AuntMinnie

JUNE 3, 2024

Eliot Siegel, MD; Stanislav Spiridonov, MD; Nathan Gee, MD; and Anthony Chang, PhD, are among a niche gathering of early adopters, entrepreneurial physicians, medical physicists, and investors with a sweet spot for nuclear medicine, diagnostic radiology, and radiation oncology.

Nuclear Medicine 264

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology 264

AuntMinnie

JULY 12, 2024

As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. A shortage of nuclear medicine technologists means a theranostics center may need to limit its patient volume.

Nuclear Medicine 264

Nuclear Medicine Radiation Oncology Radiopharmaceuticals Radiation 264

Imaging Technology

JULY 9, 2024

Campione also joins the Blue Earth Diagnostics Ltd. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., Board of Directors.

Diagnostic 105

Diagnostic Radiopharmaceuticals Nuclear Medicine Magnetic Resonance Imaging 105

AuntMinnie

DECEMBER 1, 2023

GEHC also displayed its Signa PET/MR AIR system, which was introduced at the annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in June. Pharmaceutical diagnostics The company pointed to a recent study that validated the use of AI models for predicting patient response to therapy.

Healthcare 246

Healthcare Healthcare X-ray Ultrasound 246

Imaging Technology

JUNE 15, 2023

For pharmaceutical companies and researchers, using this tracer to better understand the mechanism of action - i.e. the effect of immunotherapies on a patient’s immune response to their cancer - could, potentially, enable them to better select patients to participate in clinical trials and bring new immunotherapies to market.

Radiopharmaceuticals 98

Radiopharmaceuticals Pharmaceutical Nuclear Medicine PET Scan 98